- Pfizer has projected a 29 percent increase in the sales of its COVID-19 vaccine in 2021, to reach $33.5 billion
- Pfizer also highlighted its intent to receive an emergency use authorization in the United States by August to administer the third booster
- According to Pfizer data, administration of a third dosage produced antibodies that neutralized Covid over five-fold in younger individuals and over 11-fold among older-age individuals
NEW YORK CITY, New York: Pfizer has projected a 29 percent increase in the sales of its COVID-19 vaccine in 2021, to reach $33.5 billion.
Pfizer also highlighted its intent to receive an emergency use authorization (EUA) in the United States by August to administer the third booster.
According to Pfizer data, administration of a third dosage produced antibodies that neutralized Covid over five-fold in younger individuals and over 11-fold among older-age individuals.
“All in all, I think a third dose would strongly improve protection against infection, mild moderate disease, and reduce the spread of the virus,” Mikael Dolsten, heading Pfizer’s scientific research operations, noted in an on-call discussion.
Citing data, Dolsten noted that the indicated antibody levels could be increased to nearly 100 times, in comparison with levels seen prior to the third inoculation.
Pfizer additionally published a non-peer referred study on July 28 indicating a drop in the effectiveness of the vaccine over a period of time, decreasing to some 84-percent efficacy from 96-percent peak four months after those participating in the study were administered the second dose.
In July, health regulators in the United States did not approve Pfizer’s plan to administer a third dose on the grounds of there being insufficient data to demonstrate the necessity of booster doses.
